Compare NUAI & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUAI | RLMD |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 633.1M | 661.9M |
| IPO Year | N/A | 2012 |
| Metric | NUAI | RLMD |
|---|---|---|
| Price | $6.74 | $6.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $11.00 | ★ $12.40 |
| AVG Volume (30 Days) | ★ 8.3M | 1.3M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $0.32 | $0.52 |
| 52 Week High | $9.45 | $8.00 |
| Indicator | NUAI | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 69.98 | 50.77 |
| Support Level | $3.71 | $5.66 |
| Resistance Level | $7.59 | $7.46 |
| Average True Range (ATR) | 0.72 | 0.44 |
| MACD | 0.15 | 0.05 |
| Stochastic Oscillator | 87.33 | 73.31 |
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.